2, LB.1, KP.3 and KP.3.1.1, compared with the companies’ Omicron XBB.1.5-adapted COVID-19 vaccine.1 In July 2024, the EC granted marketing authorization for Pfizer and BioNTech’s Omicron JN.
Following the EC decision, Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine will ship to European Union (EU) member states that have specifically ordered this formulation. The CHMP ...
Results that may be inaccessible to you are currently showing.